AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in high-risk patients with early presentation
Number of subjects: 4548
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in low-risk patients with early presentation
Number of subjects: 4548
Study 19004053 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (TNF-alpha antagonist)
Number of subjects: 40
Study 16648318 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐15 mg/day)
Number of subjects: 60
Study 16648318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16648318 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 12511713 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 18
Study 12511713 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM allergen inhalation
Number of subjects: 18
Study 10368793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 IU daily for 2 months, followed by a 2-month pause, repeated for 3 cycles) and 500 mg calcium daily
Number of subjects: 24
Study 10368793 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D only (control group)
Number of subjects: 24
Study 8899498 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg positive Down syndrome patients
Number of subjects: 57
Study 8899498 — intervention group
Group type: COMPARATOR
Intervention: HBsAg negative Down syndrome patients
Number of subjects: 57
Study 8899498 — intervention group
Group type: COMPARATOR
Intervention: Mentally retarded patients without Down syndrome
Number of subjects: 57
Study 2053087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam administered at 8 am or 12 pm
Number of subjects: 0
Study 2053087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam administered at midday
Number of subjects: 0
Study 6754331 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g palatinite
Number of subjects: 24
Study 6754331 — intervention group
Group type: COMPARATOR
Intervention: 50 g glucose
Number of subjects: 24
Study 31071535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hypertonic saline injection to the vastus medialis
Number of subjects: 13
Study 31071535 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (sham)
Number of subjects: 13
Study 30217378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1834
Study 30217378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1834
Study 26890031 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D bimonthly
Number of subjects: 130
Study 26890031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 24184512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 minutes, moderate exercise on cycling ergometer)
Number of subjects: 16
Study 24184512 — intervention group
Group type: COMPARATOR
Intervention: Artificial Gravity (AG) exposure (+2Gz for 30 minutes)
Number of subjects: 16
Study 22087795 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) 500 mg
Number of subjects: 23
Study 22087795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19063686 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-34) treatment for 1 year
Number of subjects: 1
Study 19063686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on PTH)
Number of subjects: 1
Study 19063686 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-34) treatment
Number of subjects: 1
Study 16479532 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional localized spectroscopic imaging sequence
Number of subjects: 5
Study 12631508 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP fruit and vegetable intake
Number of subjects: 282
Study 12631508 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP consumption of high‐fat foods
Number of subjects: 282
Study 12631508 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared meals with FFP
Number of subjects: 282
Study 10833696 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone therapy (10 sessions of 30 minutes each)
Number of subjects: 53
Study 10833696 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 53
Study 10167365 — intervention group
Group type: EXPERIMENTAL
Intervention: School-wide media-marketing campaign, school-wide meal and snack modification, classroom workshops, parental involvement
Number of subjects: 2339
Study 10167365 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-marketing activities
Number of subjects: 2339
Study 10167365 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups for program development
Number of subjects: 2339
Study 1529682 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (2-3 units deposited preoperatively, intraoperative blood salvage used)
Number of subjects: 30
Study 1529682 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 30
Study 1529682 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 30
Study 3888336 — intervention group
Group type: EXPERIMENTAL
Intervention: Node sampling
Number of subjects: 417
Study 3888336 — intervention group
Group type: COMPARATOR
Intervention: Axillary clearance
Number of subjects: 417
Study 3888336 — intervention group
Group type: COMPARATOR
Intervention: No further surgery after node sampling
Number of subjects: 417
Study 30801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Male protagonist in 'first solo laparoscopic surgery' scenario
Number of subjects: 134
Study 30801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Male responses rating female performance
Number of subjects: 134
Study 30801508 — intervention group
Group type: COMPARATOR
Intervention: Responses to clinical performance rating and selection of action
Number of subjects: 134
Study 28554911 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL) intervention
Number of subjects: 480
Study 28554911 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 480
Study 26307511 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 90% of resting motor threshold to PMC + M1 (600 pulses each, 1200 total)
Number of subjects: 10
Study 26307511 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz rTMS at 90% of resting motor threshold to M1 (1200 pulses)
Number of subjects: 10
Study 26307511 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz rTMS at 90% of resting motor threshold to PMC (1200 pulses)
Number of subjects: 10
Study 22163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (100, 400, 4000 µg per day) for 6 months
Number of subjects: 0
Study 19459233 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher support (phone coaching plus monthly exercise support group)
Number of subjects: 92
Study 19459233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower support (phone coaching only)
Number of subjects: 92
Study 19459233 — intervention group
Group type: COMPARATOR
Intervention: Awareness (informational brochure, no coaching)
Number of subjects: 92
Study 16758422 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of primary prophylaxis
Number of subjects: 438
Study 16758422 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis
Number of subjects: 438
Study 15353377 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study 15353377 — intervention group
Group type: COMPARATOR
Intervention: Routine individual therapy
Number of subjects: 0
Study 10665618 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (24 mg/d and 30 mg/d)
Number of subjects: 850
Study 10665618 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 850
Study 10665618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 9074573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 53
Study 9074573 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (active placebo)
Number of subjects: 53
Study 9074573 — intervention group
Group type: COMPARATOR
Intervention: Saline (inert placebo)
Number of subjects: 53
Study 8459989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 3093918 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor from leukocytes of random donors
Number of subjects: 105
Study 3093918 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor from leukocytes of family members
Number of subjects: 105
Study 3093918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 3093918 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor therapy
Number of subjects: 105
Study 31714266 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation education program
Number of subjects: 80
Study 31714266 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face education (Control)
Number of subjects: 80
Study 30486630 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with Inj. Cisplatin 100 mg/m2 for three-weekly and EBRT with 60 Co/LINAC and photon radiation of 70 Gy in 35 fractions for 7 weeks.
Number of subjects: 64
Study 30486630 — intervention group
Group type: COMPARATOR
Intervention: Chemo boost with Inj. Cisplatin 6 mg/m2 on last 15 fractions of treatment and EBRT with 60 Co/LINAC photon radiation of 70 Gy in 35 fractions for 7 weeks.
Number of subjects: 64
Study 26947142 — intervention group
Group type: EXPERIMENTAL
Intervention: External Focus (EF)
Number of subjects: 9
Study 26947142 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Focus (IF)
Number of subjects: 9
Study 26947142 — intervention group
Group type: COMPARATOR
Intervention: Both EF and IF
Number of subjects: 9
Study 23768683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 12 weeks
Number of subjects: 126
Study 22169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 0
Study 22169050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (300 mg) with codeine (30 mg)
Number of subjects: 0
Study 22169050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20377504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure tonsillectomy
Number of subjects: 150
Study 20377504 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy scissors tonsillectomy
Number of subjects: 150
Study 18336971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony intramaxillary sinus septa present
Number of subjects: 75
Study 18336971 — intervention group
Group type: COMPARATOR
Intervention: No bony septa or septa < 4mm
Number of subjects: 75
Study 17065897 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microg x kg x min)
Number of subjects: 15
Study 17065897 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg) administered preventively with electrical stimulation
Number of subjects: 15
Study 17065897 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg) administered in parallel to remifentanil infusion
Number of subjects: 15
Study 17065897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 14513000 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) programme
Number of subjects: 61
Study 14513000 — intervention group
Group type: COMPARATOR
Intervention: Traditional small group tutorials
Number of subjects: 61
Study 11134918 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (CBT or psychodynamic approach) in addition to usual GP treatment
Number of subjects: 181
Study 11134918 — intervention group
Group type: COMPARATOR
Intervention: Usual GP treatment (Control)
Number of subjects: 181
Study 11134918 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (CBT or psychodynamic approach)
Number of subjects: 181
Study 9362434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg as a 2-hour infusion monthly for 2 years
Number of subjects: 751
Study 9362434 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 751
Study 1397827 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly journal club sessions with two didactic sessions before the club started.
Number of subjects: 0
Study 1397827 — intervention group
Group type: COMPARATOR
Intervention: Control group of pediatric residents at another institution.
Number of subjects: 0
Study 4029557 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distention (0, 250, 500, or 750 ml of air for 15 min)
Number of subjects: 33
Study 4029557 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distention
Number of subjects: 33
Study 31405697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Yoga Protocol (DYP) for 3 months
Number of subjects: 37
Study 31405697 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐practising)
Number of subjects: 37
Study 31405697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Yoga Protocol (DYP)
Number of subjects: 37
Study 30400122 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (45 minutes daily for 6 weeks)
Number of subjects: 60
Study 30400122 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 60
Study 27835765 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla-300)
Number of subjects: 243
Study 27835765 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100U/mL (Gla-100)
Number of subjects: 243
Study 24934333 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction during reconsolidation
Number of subjects: 0
Study 24934333 — intervention group
Group type: COMPARATOR
Intervention: Standard extinction
Number of subjects: 0
Study 23193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 56
Study 23193743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20156072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet plus weight-reducing drugs when necessary
Number of subjects: 107
Study 17934150 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial premixed therapy (PPT) - lispro mix 50/50 (50% insulin lispro protamine suspension and 50% lispro); n = 187
Number of subjects: 374
Study 17934150 — intervention group
Group type: COMPARATOR
Intervention: Basal/bolus therapy (BBT) - glargine at bedtime plus mealtime lispro; n = 187
Number of subjects: 374
Study 16463828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (2 min proximal temporary artery occlusion followed by 30 min reperfusion)
Number of subjects: 12
Study 16463828 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 12
Study 12203667 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright white light for 30 min between 6 and 9 AM
Number of subjects: 13
Study 12203667 — intervention group
Group type: COMPARATOR
Intervention: Dim red (placebo) light at a comparable time
Number of subjects: 13
Study 10510028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting disc valve (Medtronic Hall)
Number of subjects: 0
Study 10510028 — intervention group
Group type: COMPARATOR
Intervention: Bileaflet valve (St. Jude Medical)
Number of subjects: 0
Study 8536749 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler flow imaging ultrasonography (CDFI)
Number of subjects: 82
Study 8536749 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 82
Study 1960381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 1960381 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 6890839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbidilat retard forte
Number of subjects: 6
Study 6890839 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (40 mg isosorbide dinitrate as retard formulation)
Number of subjects: 6
Study 31388683 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP
Number of subjects: 185
Study 31388683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 28828764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin 0.5 units per drop 4 times per day (QID)
Number of subjects: 32
Study 28828764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin 1 unit per drop 4 times per day (QID)
Number of subjects: 32
Study 28828764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin 2 units per drop 4 times per day (QID)
Number of subjects: 32
Study 28828764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DNS)
Number of subjects: 32
Study 26998724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 150 mg daily for 8 weeks
Number of subjects: 10
Study 26998724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23787192 — intervention group
Group type: EXPERIMENTAL
Intervention: En-masse retraction with mini-implants
Number of subjects: 80
Study 23787192 — intervention group
Group type: COMPARATOR
Intervention: Two-step retraction with transpalatal arches (TPAs)
Number of subjects: 80
Study 21934167 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 70
Study 21934167 — intervention group
Group type: COMPARATOR
Intervention: Education-only (EO) condition
Number of subjects: 70
Study 19220273 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerostat‐V (ZS)
Number of subjects: 18
Study 19220273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuchamber (NC)
Number of subjects: 18
Study 19220273 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber Max (AC)
Number of subjects: 18
Study 19220273 — intervention group
Group type: COMPARATOR
Intervention: Evohaler (EH)
Number of subjects: 18
Study 18074699 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial payoffs for tasks varied between participants
Number of subjects: 60
Study 18074699 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous strategy based on initial payoffs
Number of subjects: 60
Study 15284602 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive nerve stimulation (RNS) with exercise after 20 seconds of maximal exercise at 1-minute intervals up to 3 minutes.
Number of subjects: 89
Study 15284602 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3‐Hz RNS at rest.
Number of subjects: 89
Study 11981084 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg/day orally
Number of subjects: 21
Study 11981084 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin 500 mg intravenously after each HD, in addition to folic acid
Number of subjects: 21
Study 11981084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) 60 mg/day orally, in addition to folic acid and methylcobalamin
Number of subjects: 21
Study 11981084 — intervention group
Group type: COMPARATOR
Intervention: Methylcobalamin alone (HD control group)
Number of subjects: 21
Study 9842841 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 19
Study 9842841 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 19
Study 8575497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg finasteride for 1 year, then 5 mg finasteride for 4 years
Number of subjects: 190
Study 8575497 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride for the entire 5 years
Number of subjects: 190
Study 8575497 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 190
Study 2759398 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps biopsy
Number of subjects: 23
Study 2759398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal needle biopsy (21 gauge 13-mm long metal needles)
Number of subjects: 23
Study 2759398 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic needle biopsy (18 gauge 20-mm long plastic needles)
Number of subjects: 23
Study 2759398 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage cytology
Number of subjects: 23
Study 331877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-frontal ECT (FF)
Number of subjects: 0
Study 331877 — intervention group
Group type: COMPARATOR
Intervention: Temporo-parietal ECT (TP)
Number of subjects: 0
Study 30916641 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part intervention package including a triage tool, a study-designed web page, and a brief one-to-one session based on motivational interviewing for high-risk patients.
Number of subjects: 6
Study 30916641 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 6
Study 28107680 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Treatment
Number of subjects: 211
Study 28107680 — intervention group
Group type: COMPARATOR
Intervention: Counseling Only
Number of subjects: 211
Study 25646328 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 G-allele carriers
Number of subjects: 200
Study 24238896 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 339
Study 24238896 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 339
Study 21658971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0
Study 21658971 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfocused attention
Number of subjects: 0
Study 21658971 — intervention group
Group type: COMPARATOR
Intervention: Focused attention (mindfulness)
Number of subjects: 0
Study 19478295 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month naltrexone implant
Number of subjects: 56
Study 19478295 — intervention group
Group type: COMPARATOR
Intervention: Usual aftercare
Number of subjects: 56
Study 17092597 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 18
Study 17092597 — intervention group
Group type: COMPARATOR
Intervention: Unmodified human insulin
Number of subjects: 18
Study 17092597 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart and unmodified human insulin
Number of subjects: 18
Study 14660479 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin surface cooling (SSC)
Number of subjects: 8